Heidelberg Pharma AG
XETRA:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hunan Valin Steel Co Ltd
SZSE:000932
|
CN |
Heidelberg Pharma AG
Total Equity
Heidelberg Pharma AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Total Equity
-€10.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Equity
€19.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Total Equity
€696.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Equity
€484.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Equity
€509.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Formycon AG
XETRA:FYB
|
Total Equity
€461.8m
|
CAGR 3-Years
102%
|
CAGR 5-Years
57%
|
CAGR 10-Years
43%
|
|
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
See Also
What is Heidelberg Pharma AG's Total Equity?
Total Equity
-10.9m
EUR
Based on the financial report for Nov 30, 2025, Heidelberg Pharma AG's Total Equity amounts to -10.9m EUR.
